INTRODUCTION
Carbon nanotubes with various unique physical and chemical properties have shown interesting applications in many fields, including biomedicine 1, 2 . Functionalized carbon nanotubes with water solubility and biocompatibility are able to cross cell membranes, shuttling a wide range of biologically active molecules including drugs, proteins, DNA and RNA into cells [3] [4] [5] [6] [7] . The cytotoxicity of carbon nanotubes is largely dependent on their surface functionalization, with minimal toxic effects for wellfunctionalized, serum-stable nanotubes 1, 8 . We have shown that after intravenous injection into mice, well-functionalized singlewalled carbon nanotubes (SWNTs) accumulated in reticuloendothelial systems (RES) are slowly excreted, mainly through the biliary pathway, without exhibiting obvious side effects to the treated mice 9, 10 . Recently, in vivo cancer treatment in an animal model has been realized by carbon nanotube-based drug delivery 11 .
Carbon nanotubes are classified as single-walled carbon nanotubes (SWNTs) and multi-walled carbon nanotubes (MWNTs), depending on the number of graphene layers from which a nanotube is composed. SWNTs are quasi-one-dimensional quantum wires with sharp densities of electronic states (electronic DOS) at the van Hove singularities and generally have more attractive unique intrinsic optical properties than MWNTS. SWNTs can be used as optical tags for biomedical detection and imaging [12] [13] [14] [15] [16] [17] [18] . Ultra-sensitive ex vivo protein sensing with a detection limit as low as 1 fM using SWNT Raman tags has been achieved using the resonance Raman scattering property of SWNTs and surfaceenhanced Raman scattering (SERS) 14 . The Raman scattering, near-infrared (NIR) photoluminescence and high optical absorbance of SWNTs have all been used for biomedical molecular imaging in vitro and in vivo [15] [16] [17] [18] . Thus, carbon nanotube bioconjugates are promising nanomaterials for biomedical applications.
SWNTs may have various potential advantages over other nanomaterials in different areas of nanobiotechnology. As an optical tag in biological imaging, SWNTs can be used in Raman, NIR fluorescence and photoacoustic imaging of cells and animals 12, 13, [15] [16] [17] [18] . Multimodality optical imaging could thus be achieved using SWNTs as the contrast agent. Quantum dots or surface-enhanced Raman scattering gold/silver nanoparticles normally only have a single imaging functionality 19, 20 . In contrast to widely used fluorescent quantum dots, carbon nanotubes contain no heavy metals and thus have a safer chemical composition. In the area of drug delivery, SWNT-based siRNA delivery works for a large range of cells, including notoriously 'hard-to-transfect' human T cells 4 , which are inert to conventional liposomal transfection agents. SWNTs can be efficiently loaded with aromatic chemotherapy drugs such as doxorubicin (DOX) through supramolecular p-p stacking 21 , obtaining an ultra-high loading capacity superior to other drug carriers including liposomes and micelles. Moreover, the high optical absorbance of SWNTs can also be used in photothermal therapy 22, 23 , which may potentially be combined with chemotherapy 11, 21 and gene therapy 4, 24 , both delivered by SWNTs to treat cancer in a more efficient manner.
For biomedical applications, raw hydrophobic SWNTs must be functionalized to afford water solubility and biocompatibility. Our previous studies have uncovered that the behaviors of SWNTs in biological systems in vitro (such as cellular uptake) and in vivo (such as blood circulation time and biodistribution) are highly dependent on their surface chemistry 4, 9, 25 . Developing proper surface functionalization on SWNTs is thus the most critical step to produce nanotube bioconjugates for a desired application. There are two major types of functionalization protocols for SWNTs: covalent reactions or non-covalent coating by amphiphilic molecules on nanotubes. Various covalent functionalization reactions, such as oxidation 26, 27 of nanotubes and 1,3-dipolar cycloaddition 28 on the nanotube sidewalls, have been developed to produce watersoluble nanotubes useful in certain biomedical applications such as drug delivery 2 . Although covalent chemical reactions often allow stable functionalization on carbon nanotubes, the properties of SWNTs are degraded when the nanotube sidewall is damaged, dramatically decreasing the Raman scattering and NIR fluorescence signals of SWNTs 1 . Therefore, covalently functionalized carbon nanotubes have been widely used in drug and gene delivery 2, 29 , but are usually not ideal for sensing and imaging applications 1 . In contrast, the structure and optical properties of SWNTs are largely maintained when non-covalent functionalization is used. However, the stability and biocompatibility of many non-covalently functionalized SWNTs are not satisfactory. For example, SWNTs solubilized in small-molecule surfactants (e.g., sodium dodecyl sulfate, SDS) will aggregate and precipitate if excess coating molecules are removed. An ideal functionalization should impart SWNTs with high water solubility, biocompatibility, minimal damage of nanotube structure and functional groups available for further bioconjugation.
Our group has developed systematic protocols for SWNT functionalization and bioconjugation in the past few years. Raw SWNTs are non-covalently functionalized by amphiphilic polymers, such as phospholipid-poly(ethylene glycol) (PL-PEG) 6, 22 . Functionalized SWNTs have excellent stability in the aqueous phase and are highly biocompatible. Targeting ligands including antibodies and peptides can be conjugated to SWNTs to recognize specific cell receptors, yielding targeted SWNT bioconjugates useful for biological sensing 14 and imaging [15] [16] [17] [18] . We have also developed a protocol to label SWNTs with radioactive isotopes to track and image nanotubes in vivo by positron emission tomography (PET). In addition, SWNT-based siRNA transfection can be achieved by conjugating siRNA to SWNTs through a cleavable disulfide bond 4, 6 . Furthermore, aromatic drug molecules can be non-covalently loaded onto SWNTs by simple mixing for drug delivery 21 .
Here, we systematically summarize the nanotube functionalization and bioconjugation protocols developed and used in our previous studies. Although our bioconjugation strategies apply for a wide range of biomolecules, only a few model systems are chosen to illustrate those protocols. Arg-Gly-Asp (RGD) peptide and Herceptin anti-Her2 antibody are used as targeting ligands. 64 Cu is reported as an example of radiolabeling SWNTs. Anti-CXCR4 siRNA is chosen for siRNA conjugation and delivery. Finally, DOX is shown as an aromatic drug, loaded onto SWNTs for drug delivery. These detailed protocols should be beneficial to scientists interested in further developing biological applications of novel nanomaterials.
Experimental design
Non-covalent functionalization of SWNTs by PL-PEG. SWNTs are non-covalently functionalized by sonication of raw, hydrophobic nanotubes in water solutions of amphiphilic polymers (e.g., PL-PEG) 6, 22 . The hydrophobic lipid chains of PL-PEG are strongly anchored onto the nanotube surface, whereas the hydrophilic PEG chain affords SWNT water solubility and biocompatibility. After removal of excess PL-PEG molecules, functionalized SWNTs show excellent stability in various aqueous phases including water, physiological buffers (e.g., phosphate buffered saline, PBS), cell medium and whole serum. The concentration of a SWNT solution can be determined by its optical density at 808 nm measured by a UV-VIS-NIR spectrometer with a weight extinction coefficient of 0.0465 mg l À1 cm À1 (dividing the optical density at 808 nm by the extinction coefficient gives the concentration) 22 . The length distribution of functionalized SWNTs can be determined by an atomic force microscope (AFM). Those non-covalently functionalized SWNTs retain their Raman and NIR fluorescence properties and are useful in biological detection and imaging applications. The functional group (e.g., amine) on the PEG terminal is available for further bioconjugation (Fig. 1) .
Conjugation with targeting ligands. Targeting ligands including antibodies and peptides can be conjugated to SWNTs to recognize specific cell receptors (Fig. 2) . Herceptin is a monoclonal antibody that binds specifically to the Her2/neu receptor over-expressed on a wide range of human breast cancer cells 30 . The RGD peptide targets integrin a v b 3 receptors that are upregulated on fast-growing tumor vasculature cells and many types of cancer cells 31 . The antibody Herceptin is first thiolated by Traut's reagent following standard protocols 15, 16 and used immediately after purification. The Traut's reagent reacts with amino groups on the antibody and produces active thiol groups useful for bioconjugation. Thiolated RGD peptide synthesized following a previously published protocol 32 is used directly. The thiolated antibody or peptide should be protected from oxidation by adding EDTA to prevent heavy metal-catalyzed oxidization, or Tris-(2-carboxyethyl)phosphine hydrochloride (TCEP) as a reducing agent, during the conjugation with nanotubes. Maleimide groups are introduced onto SWNTs by reacting PL-PEG-amine-functionalized SWNTs with a sulfosuccinimidyl 4-N-maleimidomethyl cyclohexane-1-carboxylate (Sulfo-SMCC) bifunctional linker. The activated SWNTs are then reacted with thiolated antibodies or peptides, obtaining targeted SWNT bioconjugates, which can be used in multiplexed Raman spectroscopic imaging 15, 18 , ultra-sensitive Raman detection of proteins 14 , NIR fluorescence imaging 16 , photoacoustic imaging 17 and targeted photothermal therapy 22, 23 . The targeting ability of SWNT bioconjugates (e.g., SWNT-RGD) can be characterized by in vitro Raman spectroscopic imaging experiments, in order to examine the staining of integrin a v b 3 -positive U87MG cells and a v b 3 -negative MCF-7 cells incubated with the SWNT-RGD conjugate. Step 6A and B are conjugation of targeting ligands to SWNTs.
Step 6C is radiolabeling of SWNTs.
Step 6D is siRNA conjugation to SWNTs.
Step 6E is doxorubicin loading onto functionalized SWNTs.
Radiolabeling of SWNTs. To image and track SWNTs in vivo by PET, SWNTs are labeled with a radioactive isotope (Fig. 3) 25 .
PET imaging provides three-dimensional distribution information of radiolabeled nanotubes in live mice in real time.
To obtain RGD-conjugated radiolabeled SWNTs, SWNTs are first reacted with a mixture of sulfo-SMCC and N-hydroxysuccinimide (NHS) activated 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and then conjugated to RGD-SH. After removal of excess reagents, 64 Cu radioactive isotope can then be complexed to the DOTA rings on the SWNTs to achieve radiolabeling. The radiolabeled, targeted SWNT bioconjugate can then be used for in vivo PET imaging of mice bearing integrin a v b 3 -positive, e.g., U87MG human glioblastomas tumors 25 . A total of 5-10 million of U87MG cells should be injected subcutaneously on the shoulder of a nude mouse. The mice can be used 2-3 weeks after tumor inoculation. PET imaging should be carried out at 0.5, 2, 4, 6 and 24 h post injection (p.i.). Mice may be killed at 24 h p.i. when the blood circulation of nanotubes has ended.
siRNA conjugation to SWNTs through cleavable disulfide bond.
The intracellular molecular delivery ability of SWNTs can be used for siRNA transfection 4, 6 . In this example we chose to use CXCR4, a chemokine receptor that has an important role in the entry of HIV virus into human T cells 33 . SWNTs are first reacted with a bifunctional linker, Sulfosuccinimidyl 6-(3'-[2-pyridyldithio]-propionamido)hexanoate (Sulfo-LC-SPDP) and then conjugated with thiolated siRNA through a cleavable disulfide bond (Fig. 4) DOX loading on functionalized SWNTs. SWNTs, with all atoms exposed on their surface, have an ultra-high surface area available for binding of aromatic molecules through supramolecular p-p stacking 21 . Functionalized SWNTs with or without targeting ligands can be loaded with DOX, an aromatic chemotherapy drug used for various types of cancers, by simply mixing the two solutions at a slightly basic pH. Excess unloaded DOX can be removed by filtration. The optical absorption of SWNT-DOX at 490 nm after subtraction of the SWNT absorption (at the same nanotube concentration) can be used to calculate the DOX concentration and loading in the SWNT-DOX complex 21 .
On the basis of the UV-VIS-NIR absorption spectra, up to 4 g of DOX can be loaded on 1 g of SWNTs. The toxicity of SWNT-DOX is lower than that of free DOX but can be enhanced when conjugated with a targeting ligand such as RGD peptide for targeted drug delivery. Toxicity assays can be carried out by testing cell viabilities after incubating cells with free DOX, SWNT-DOX and SWNT-RGD-DOX at series of DOX concentrations using a CellTiter 96 kit (Promega). Samples should be measured in triplicate and the cell viability should be determined compared with that of the untreated control, defined as 100% viable. . PL-PEG5000-Amine (NOF Corporation, cat. no.
DSPE-050PA)
. PL-PEG2000-Amine (NOF Corporation, cat. no.
DSPE-020PA)
. RGD peptide (c(RGDyK); Peptides International) . Thiolated RGD peptide (see REAGENT SETUP) . Herceptin (Genentech) . Sulfo ' PAUSE POINT The PL-PEG-functionalized SWNT solution can be stored at 4 1C for 1-2 months before bioconjugation. It is highly recommended to store SWNT solutions in the presence of excess PL-PEG (e.g., before the removal of excess PL-PEG in
Step 5).
5| Add 1 ml of SWNT solution from the stock prepared in Step 3 into a 4-ml Amicon centrifugal filter device with a molecular weight cutoff (MWCO) of 100 kDa. Add 3 ml of water and centrifuge the device for 10 min, at 4,000g, room temperature. The leftover volume in the filter should be o0. Step 5. Add 60 ml of PBS (10Â). Let the reaction occur at room temperature for 2 h. (ii) Remove excess Sulfo-SMCC using an Amicon centrifugal filter device (MWCO ¼ 100 kDa). Wash 5-6 times as described in
Step 5. Add water to a final volume of 0.5 ml. m CRITICAL STEP The final SWNT solution should be immediately mixed with thiolated Herceptin. (iii) Immediately after the Sulfo-SMCC reaction with SWNTs is started (Step 6B(ii)), weigh 1-2 mg of Traut's reagent into a 2-ml plastic tube. On the basis of weight, add the desired volume of water so that the final concentration of Traut's reagent is 5 mM. In a plastic tube, add 6 ml of 140 mM Herceptin, 10 ml of 1Â PBS, 1.7 ml of Traut's reagent solution and 1 ml of 0.5 M of EDTA solution. The molar ratio of Traut's reagent/antibody is about 10:1. Incubate the reaction solution for 1.5-2 h at 4 1C. (iv) Add 300 ml of 1Â PBS into the solution prepared in Step 6B(iii), remove the excess Traut's reagent by filtration using a Microcon Ultracel YM-100 filter device. Centrifuge for 6-8 min at 10,000g, room temperature until the leftover volume is o10 ml. m CRITICAL STEP Use the thiolated Herceptin immediately. 64 Cu by filtration using a Microcon Ultracel YM-100 filter device. Centrifuge for 6-8 min at 10,000g until the leftover volume is o10 ml. Wash 3-4 times by adding 200-300 ml of water and centrifuge for 6-8 min at 10,000g each time. Resuspend the final labeled SWNTs in 500 ml of 1Â PBS (SWNT concentration B10 mg l À1 ). Determine the radiolabeling yield by g-counting.
! CAUTION Radio isotope waste including contaminated devices such as filters should be collected and disposed in designated containers shielded with lead.
? TROUBLESHOOTING (viii) Inject 150 ml of B10 mg l À1 radiolabeled SWNTs (Step 6C(vii)) into U87MG tumor bearing mice through the tail vein.
! CAUTION Obtain appropriate training regarding animal handling. Animal protocols must be in place before performing animal studies. Mix 15 ml of 100 mM siRNA (siRNA CXCR4 or siRNA luc ) with 1.5 ml of DTT solution. Allow the reaction to proceed for 1.5 h at room temperature. (iii) After Step 6D(i), remove the excess Sulfo-LC-SPDP from the SWNT solution using an Amicon centrifugal filter device (MWCO ¼ 100 kDa). Wash 5-6 times by adding 3-4 ml DNase/RNase-free water and centrifuge for 6-8 min at 10,000g each time. The leftover volume in the filter should be o0.5 ml. m CRITICAL STEP The obtained activated SWNTs should be used immediately for siRNA conjugation. (iv) After Step 6D(ii), and in parallel with Step 6D(iii), purify DTT treated with the siRNA using a NAP-5 column following the manufacturer's protocol. Elute the siRNA from the column with 500 ml of DNase/RNase free 1Â PBS. (v) Resuspend the activated SWNTs from Step 6D(iii) with the 500 ml of purified siRNA solution from Step 6D(iv). Allow the conjugation to proceed for 24 h at 4 1C. The final SWNT and siRNA concentrations are B40 mg l À1 and B2.5 mM, respectively. m CRITICAL STEP Use the SWNT-siRNA conjugate immediately after synthesis. This will reduce the chance of bacteria contamination and siRNA degradation. (vi) For the siRNA transfection, plate CEM.NK R cells in a 24-well plate with 500 ml of cells per well. The cell density should be B1 Â 10 5 cells per ml. (vii) To remove aggregates, centrifuge the SWNT-siRNA solutions prepared in Step 6D(v) for 10 min, at 10,000g, 4 1C. Collect the supernatant containing either SWNT-siRNA CXCR4 or SWNT-siRNA luc conjugates and add 100 ml to each well of cells. The final SWNT and siRNA concentrations are B10 mg l À1 and B500 nM, respectively, in the cell medium. (viii) Transfect CEM.NK R cells with 500 nM siRNA CXCR4 using commercial transfection agents (e.g., Lipofectamine2000 (Invitrogen), LipofectamineRNAiMAX (Invitrogen), siPORT (Ambion) and HiPerFect (Qiagen)) following the manufacturers' protocols. The samples need to be centrifuged (7 min, 300g, room temperature) and collected before the wash step. 
TIMING
Steps 1-5, Functionalization of SWNTs: 1-2 d
Step 6A, Conjugation of SWNTs with RGD peptide: 3 d
Step 6B, Conjugation of SWNTs with antibody (Herceptin): 2 d
Step 6C, Radiolabeling of SWNTs: 5 d
Step 6D, siRNA conjugation on SWNTs: 5-6 d
Step 6E, DOX loading on functionalized SWNTs: 5-6 d
? TROUBLESHOOTING Troubleshooting advice can be found in signals on integrin a v b 3 -positive U87MG cells but not on a v b 3 -negative MCF-7 cells (Fig. 6a) . Nonspecific binding of SWNTs to MCF-7 cells should be minimal. The ratio of Raman signals on positive versus negative cells is 440 (Fig. 6b) . Raman imaging of BT474 (Her2-positive) and MCF-7 (Her2-negative) cells after staining with SWNT-Herceptin (Step 6B) should give very similar results (data not shown). Those targeted SWNT bioconjugates may also be used in ultra-sensitive protein microarray detection 14 .
Radiolabeled SWNTs for in vivo PET imaging and tumor targeting In Step 6C(ix), PET images ( Fig. 7 ) at 6 h p.i. should show high tumor uptake (10-15%ID/g) in U87MG tumor bearing mice injected with SWNT-RGD (functionalized by PL-PEG5000) 25 . Radiolabeled SWNTs without RGD conjugation should show a reduced uptake in the tumor (3-5%ID/g) in comparison with RGD-conjugated SWNTs. Tumor uptake will be significantly reduced if mice are pre-injected with a high dose of free RGD peptide before injection of SWNT-RGD (4-6%ID/g). Control integrin a v b 3 -negative HT29 tumors should have a lower uptake of SWNT-RGD (3-5%ID/g) (Fig. 7d) .
SWNT-based siRNA transfection and RNAi effect In Step 6D(vii), as shown in Figure 8 , . SWNT-DOX has relatively lower toxic effect than free DOX to both types of cells, whereas SWNT-RGD-DOX exhibits increased toxicity to U87MG cells but not to MCF-7 cells. Cell viability was calculated by normalizing to the untreated control sample, which is determined as 100%. Error bars are based on standard deviations of triplicate samples. This figure is adapted from our previously published work and reproduced with permission from ACS Publications 21 .
commercial cationic liposome-based siRNA transfection agents do not show significant siRNA transfection effects to CEM.NK R cells because human T cells are well known to be difficult to transfect.
DOX loading on functionalized SWNTs
In Step 6E, the SWNT-DOX solution is reddish in color because of the UV-VIS absorption of DOX stacked onto SWNTs (Fig. 9a) . The DOX absorption peak at 490 nm after subtraction of SWNT absorption at this wavelength is used to determine DOX concentration (Fig. 9b) . In Step 6E(iv), SWNT-DOX has a lower toxicity than free DOX. Conjugation of RGD enhances the toxicity of DOX-loaded SWNTs to integrin a v b 3 -positive U87MG cells but not to a v b 3 -negative MCF-7 cells (Fig. 9c,d 
